OnKure Therapeutics Operating Income 2020-2024 | OKUR

OnKure Therapeutics operating income from 2020 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.

OnKure Therapeutics Operating Income 2020-2024 | OKUR

OnKure Therapeutics operating income from 2020 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$88.1B
Takeda Pharmaceutical (TAK)$44.8B
Merck (MKGAF)$21.8B
Astellas Pharma (ALPMY)$20.6B
Sandoz Group AG (SDZNY)$18.4B
Summit Therapeutics (SMMT)$17B
United Therapeutics (UTHR)$16.5B
Shionogi (SGIOY)$12.2B
Neurocrine Biosciences (NBIX)$12B
Catalent (CTLT)$10.9B
Orion OYJ (ORINY)$7.4B
Jazz Pharmaceuticals (JAZZ)$7.1B
Ionis Pharmaceuticals (IONS)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.5B
Corcept Therapeutics (CORT)$4.9B
Crinetics Pharmaceuticals (CRNX)$4.7B
Madrigal Pharmaceuticals (MDGL)$4.7B
Dyne Therapeutics (DYN)$3.6B
PTC Therapeutics (PTCT)$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
Soleno Therapeutics (SLNO)$2.1B
Recursion Pharmaceuticals (RXRX)$2B
Harrow (HROW)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
Ocular Therapeutix (OCUL)$1.8B
NewAmsterdam Pharma (NAMS)$1.7B
ARS Pharmaceuticals (SPRY)$1.6B
BioCryst Pharmaceuticals (BCRX)$1.6B